Product Description
Angiopoietin-like 3 protein (ANGPTL3) is an inhibitor of both lipoprotein lipase and endothelial lipase in humans. Population studies indicate a relationship between loss of function mutations in ANGPTL3 and favorable reductions in triglycerides and non- high-density lipoprotein cholesterol. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31008773/)
Mechanisms of Action: LIP Inhibitor,LPL Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: Kyttaro
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lipodystrophy, Familial Partial|Hyperlipidemia|Hyperlipoproteinemia Type I|Familial Chylomicronemia Syndrome|Protein Deficiency|Hyperlipoproteinemia Type II|Hypercholesterolemia|Hyperlipoproteinemias
Phase 1: Hypertriglyceridemia|Hyperlipoproteinemia Type II|Hypercholesterolemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ISIS 703802-CS5 | P2 |
Completed |
Lipodystrophy, Familial Partial |
2019-07-30 |
|
| ISIS 703802-CS4 | P2 |
Withdrawn |
Hypercholesterolemia|Hyperlipoproteinemia Type II |
2018-09-30 |
22% |
| ISIS 703802-CS4 | P2 |
Withdrawn |
Hypercholesterolemia|Hyperlipoproteinemia Type II |
2018-09-30 |
22% |
| ISIS 703802-CS3 | P2 |
Completed |
Protein Deficiency|Hyperlipoproteinemias|Hyperlipidemia|Hyperlipoproteinemia Type I|Familial Chylomicronemia Syndrome |
2018-06-12 |
|
| ISIS 703802-CS1 | P1 |
Completed |
Hypertriglyceridemia|Hyperlipoproteinemia Type II|Hypercholesterolemia |
2017-04-12 |
59% |